| BURU 0.2231 0.86% | PLUG 3.81 34.63% | ASNS 0.6247 68.84% | DFLI 1.89 76.64% | CHR 0.1609 22.64% | OPEN 8.11 1.25% | SOXS 4.69 1.96% | BNAI 0.6015 69.44% | TSLL 19.63 -2.92% | RKT 17.8 -3.10% | LAC 9.04 31.78% | SNAP 8.54 3.89% | RGTI 40.06 13.16% | NVDA 187.62 -0.67% | TSLA 429.83 -1.42% | CAN 1.31 -0.76% | INTC 36.83 -1.26% | SQQQ 15.05 1.42% | DNN 2.8 1.08% | QUBT 24.62 23.22% | PSLV 16.13 2.35% | GPUS 0.54 11.57% | ACHR 11.57 13.65% | PLTR 173.07 -7.47% | RR 6.18 19.77% | F 12.67 3.68% | QBTS 32.7 11.95% | BBAI 7.19 -1.10% | TLRY 1.62 0.62% | TSLQ 8.51 2.78% | IBIT 69.81 1.51% | SOFI 25.24 -2.81% | AAL 11.58 1.31% | IONZ 3.4 -11.92% | QS 15.92 11.33% | SOUN 17.85 0.06% | DVLT 1.34 -12.42% | ONDS 9.91 7.60% | PFE 27.37 1.07% | SOXL 38.23 -2.18% | CIFR 14.7 6.44% | SPY 669.21 0.00% | HIVE 4.45 2.06% | CJET 0.169 -0.59% | BITF 3.01 2.73% | BBD 3.17 0.11% | SHOT 0.3702 31.74% | ANRO 6.89 56.24% | NIO 7.7 -2.41% | MARA 18.82 0.16%
Article image

Tilray Brands, Inc. (NASDAQ: TLRY) Quarterly Earnings Preview

Tilray Brands, Inc. (NASDAQ: TLRY) is a prominent player in the cannabis industry, known for its diverse product offerings and strategic acquisitions. The company has expanded its portfolio beyond cannabis, acquiring craft beer brands from Anheuser-Busch InBev, which has helped balance its revenue streams. Despite its growth, Tilray's stock has faced volatility, trading significantly below its peak in 2018.

On October 9, 2025, Tilray is set to release its quarterly earnings, with Wall Street estimating an earnings per share (EPS) of -$0.03. This represents a 25% improvement from the same quarter last year, indicating progress in the company's financial performance. Revenue is projected to be approximately $205.75 million, slightly below the expected $206.83 million, yet still marking a 3.39% increase from the previous year.

Recently, Tilray's stock price closed at $1.66, a 4.34% decrease despite broader market gains. This decline contrasts with the company's impressive 38.4% surge over the past month, outperforming both the Medical sector and the S&P 500. The stock's recent rally, driven by political news and increased trading volume, has sparked investor interest and speculation about its long-term value.

Tilray's financial metrics reveal a complex valuation scenario. The company has a price-to-sales ratio of approximately 1.60 and an enterprise value to sales ratio of 1.61, suggesting a reasonable valuation relative to its sales. However, the negative price-to-earnings ratio and earnings yield indicate current unprofitability, while the negative enterprise value to operating cash flow ratio highlights challenges in generating cash flow.

Despite these challenges, Tilray maintains a strong cash position and a low debt-to-equity ratio of 0.16, reflecting financial stability. The current ratio of 2.46 further underscores its ability to cover short-term liabilities. As investors anticipate the upcoming earnings release, Tilray's diversified business model and strategic positioning continue to attract attention in the evolving cannabis market.

Published on: October 2, 2025